Basem Goueli, M.D., Ph.D., MBA

Contributor   in
The Insider's Guide to Translational Medicine  

Dr. Goueli has directed three independent cancer institutes, collectively representing 17 hospitals and 12 cancer centers. He is a hematologist and medical oncologist who has been the institutional principal investigator on nearly 100 clinical trials involving breast cancer, myeloma, prostate cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, myelodysplastic syndrome, CLL, DLBCL, esophageal cancer, etc. He is board-certified in hematology, medical oncology, internal medicine, and artificial intelligence in medicine.

Dr. Goueli's training includes:

MD: Mayo Clinic
PhD in biochemistry: Mayo Clinic
MBA: University of North Carolina, Chapel Hill
Internal Medicine Residency: George Washington University Hospital with 4 months at the NIH
Hematology/Oncology Clinical Fellowship: Stanford
Biochemistry Post-Doctoral Fellowship: Stanford
MIT Xpro Course Certificate: Designing Artificial Intelligence Products
MIT Xpro: Course Certificate: Robotics Essentials
MIT Xpro: Course Certificate: Drug and Medical Device Development
MIT Professional Education Course Certificate: Applied Data Science Bootcamp

Dr. Goueli resisted the trend toward subspecialization during his career as he felt ideation often happens at the level of the forest, not the trees. It's his firm belief many of the greatest future innovations will be at the interface of various disciplines.

Dr. Goueli's area of clinical expertise is precision medicine, and his ability to treat patients in all hematology/medical oncology disciplines uniquely positions him to sequence molecular-based therapies in the context of conventional therapy and clinical trials.

Dr. Goueli is the CEO and Founder of two companies, CancerClarity and CancerLight. They are early in development and hope to disrupt the clinical trial, patient education, and clinical care forums. Aside from running his two companies, Dr. Goueli is consulting medical director and medical monitor for 3 phase 1 Xbiotech clinical trials, consults for numerous other pharmaceutical companies, and sees patients full-time in the clinic as a hematologist/medical oncologist.

tags:   Oncology     Biomedical Research    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at platform are their own personal points of view, and do not represent neither Contributor's employers, nor

Posts by this author

Playing Chess Against Cancer: A Pharmaceutical, Biotechnological, and Clinical Guide to Modern Day Oncologic Treatment Cartography

Playing Chess Against Cancer:  A Pharmaceutical, Biotechnological, and Clinical Guide to Modern Day Oncologic Treatment Cartography

We are witnessing a revolution in cancer therapeutics that is truly bewildering. The number of novel drugs with unique mechanisms of action currently in clinical trial and development is staggering, and will only increase. Much of this has been precipitated by exponential advances in computational biology and precision medicine. To this end, many oncologic breakthroughs in the future will occur at the intersection between these disciplines and the clinic. Thus, understanding the putative clinical relevance and utility of drug development and precision medicine endeavors is essential for related companies, academic researchers, etc. Failure to derive a sophisticated appreciation of how one's work will translate into the clinic can be catastrophic, as you can have "positive related studies" with no clinically applicable "end-game" or return on your investment. Failure of oncologists to develop a strategy for assimilating molecular data and novel agents they will be inundated with in the future will compromise patient care. In this bimonthly editorial series, we strive to ensure readers have clear visibility of the "clinical forest", and not just the associated "trees". We will focus on the present and the future of precision medicine as it relates to the clinic, and provide those in the pharmaceutical industry with an instrumental clinical perspective. We start by introducing the notion of "playing chess against cancer" through treatment cartography, the development of patient specific treatment maps incorporating conventional therapies, clinical trials, molecular studies, etc.

Conducting a Cellular Symphony With Life Saving Combination Therapies

Conducting a Cellular Symphony With Life Saving Combination Therapies

I always think of the Jeff Goldblum quote in Jurassic Park where he says "life finds a way" when I think of cancer. However, I simply substitute the word life with cancer in that "cancer finds a way". Indeed, the bane of an oncologist's existence is the heterogeneity of tumors and the numerous resistance mechanisms cancer cells employ. One of the most fundamental questions in Oncology is why we can't cure the vast majority of stage 4 tumors even though we can often eradicate large swaths of tumor cells.